Skinbiotherapeutics Share Discussion Threads

[parob] 18/4/2018 13:38

Buy after buy flying in and still under the radar. This feels like it could blow soon, just like N4P did once it broke 12p.

[bobalot] 18/4/2018 11:01

Very interesting interview:

'Huge milestone' for SkinBioTherapeutics with cream formulation success

Dr Cath O'Neill, chief executive of SkinBioTherapeutics PLC (LON:SBTX), tells Proactive Investors the 'cream' formulation of its SkinBiotix technology has passed effectiveness studies in models of skin.

[onedayrodders] 18/4/2018 10:04

I take it back what I said yesterday about the gel and lotion will follow in separate RNS's.

After hearing the proactive interview my take is they are actually not overly bothered now the science works in a formula. This is all they need to take to trial and sign licencing deals.

[onedayrodders] 18/4/2018 10:01

"The share price is holding very well" .. usually the kiss of death

[bobalot] 17/4/2018 18:12

The share price is holding very well...perhaps we are entering an upward trend after all the resistances have been broken, leaving behind support levels.

WE might be entering an upward channel after a triple drop a few weeks ago signalling an aggressive uptrend in the share price ..IMO.

THE share price IS LOOKING VERY BULLISH ON TODAY'S NEWS RELEASE.

[rafboy] 17/4/2018 16:35

She mentioned September for the trial date. Another positive interview and things are shaping up quite nicely here.

[elrico] 17/4/2018 15:59

Very good key points in the interview I don't mind admitting I wasn't aware of...."Great technology can be screwed up by formulation. " Clearly more important than perhaps credited and gel's and lotion formulation to be tested.

[parob] 17/4/2018 15:02

New interview with Cath just out.

'Huge milestone' for SkinBioTherapeutics with cream formulation success

[bobalot] 17/4/2018 13:37

Dr. Cath and her professor are a CLASS ACT they know their stuff inside-out..the development of the Gel and Lotion is just a formality. and an even larger resulting market along with many more opportunities. The ingredients of the cosmetic cream could be used perhaps in Sun Screen lotion providing protection from infections while giving the skin tone behind the tan more radiance.

There are so many angles on these products it has to become a market leader in at least three sectors...imo.

[rathean] 17/4/2018 09:43

Impressive progress and this continues on quite a steep upward trend. Too early for an N4P effect or timing ahead of trials just about right? Either way happy to be in here at such low prices.

[bobalot] 17/4/2018 09:18

Human trials start in Q3 so they have just a few months to finalise the formulations for the Gel and Lotion....Dr. Cath looks very confident imo.

Buying has now started at 11p:

Skinbiotherapeutics PLC
LON: SBTX
11,00 GBX +1,25 (12,82%)
17.04, 09:11

[toadhall1] 17/4/2018 09:14

Yes so great news. So direct correlation of the protein in the skin to the amount of probiotic lysate extract in the cream. That clearly helps them accurately determine the level of dosing required to ensure the desired level of effectiveness of the product. Stability tests of the cream to follow. I guess another key test as you don't want the ingredients separating out in the bottle/transit etc. They are also effectively saying that the gel and lotion haven't quite reached their high levels of satisfaction yet. So more work to continue on refining those products.

[bobalot] 17/4/2018 08:01

tHIS PART IS VERY INTERESTING shows a direct correlation, meaning the strength or effectiveness of the cream to enhance the skins barrier to infection can be controlled. And there will be three cosmetic products presented as a cream, gel and lotion....all very large target markets imo.


The data further showed a direct correlation between the amount of SkinBiotix(R) within the cream and the level of the protein present. Work on creating skin lotion and gel formulations is ongoing.

[nig1954] 17/4/2018 07:09

Confirmation of the formulation of creams may help to nudge this share in the right direction and become the beginning of a share price rerate given all the other good news in the pipeline.gla

[owenmo] 16/4/2018 15:39

Why is that Parob, has there been an Investor Show to-date that sparked a scintilla of interest in our beloved SBTX and OPTI?

[onedayrodders] 15/4/2018 16:38

I'll be there and will feedback anything worthwhile

[parob] 15/4/2018 12:42

SkinBioTherapeutics will be exhibiting at the UK Investor Show on Sat 21st April. Should hopefully drum up more investor interest in the company.

[parob] 15/4/2018 12:33

The Role of the Skin Microbiome in Atopic Dermatitis (Eczema)hTTps://www.slideshare.net/mobile/LauraBerry22/the-role-of-the-skin-microbiome-in-atopic-dermatitis-eczema

[shrewdmole] 14/4/2018 10:55

Elrico

Great post and insight.

My comments are more from a trading activity view.

The last week or so we've started to see increased volume and an improvement on the share price performance.

A close above 10p could see a decent run purely as it will have broken through ceiling. Some very nice buys been going through.

I'm heavily in here already but am very tempted to add at these levels.

I still think a commercial tie up could be done prior to the human trials so the Mn partner can have input into them.

Let's not forget the dosage tests etc have been done in human skin samples already so what are the chances of success?

At this current market cap it could be a real winner in time.

S

[bobalot] 13/4/2018 16:12

Elrico very good and informative views...SBTX is in the right pace at exactly the right time...The article published yesterday about developments in the Korean market underscores that view.

Beyond beauty: Korean makeup provides 'cosmeceuticals'

[elrico] 13/4/2018 15:44

At the risk of falling into a trap...Paul - post 1486 is NOT a "Hybridan article" they are my personal views, with valuations of Hybridan as an illustration of SkinBiotix's huge potential. From memory, Hybridans valuation was prior the proof of concept, scientific validation, hence the high risk it put on SkinBiotix of failing. History now tells us the science works, thus we wait the final validation; human trials data. I also wanted to put across industry valuation (with assumptions all goes according to plan). I think we all agree SBTX has huge potential and by following the parent company's commercial footprint, SBTX will almost certainly multi-multi-bag from here in due course; but patience will be required. We must learn from OPTI's story, MN partners move at their pace, not at PI's pace.

There are no further funding requirements, no marketing spend, and ongoing R&D done on the cheap via UoM labs, this all points to low PLC costs where partners pickup the marketing tab while SBTX reaps the royalties, etc.

IMHO Cath has learned from SOH, which is why I suggest the MTA is a smart move and one that has the potential to speed up the commercial process by essentially getting the DD out of the way ahead of the human trial data. The question remains, is it J&J or another global corporate? The more I think about it, the more I'm inclined to think I am wrong in my first guess (J&J) because logic suggests J&J have been working very closely with SkinBiotix since June 2014, so I think it's a safe assumption there could be another global corporate in line to use SBTX IP. IF I am correct, this is a fantastic development for SBTX.

[paulhoodwinked] 13/4/2018 14:56

Coming from the master of repetitive info that would be quite funny if it wasn't so foolish. How is it old repetitive rubbish? Have i missed something? Don't you agree with the hybridan valuation?